34.05

1.26% 0.425

Roivant Sciences Ltd (ROIV)

Overview News Price History Option Chain Financials Discussions Forecast

Roivant Sciences Ltd stock is traded at $34.05, with a volume of 1.49M. It is up +1.26% in the last 24 hours and down -13.81% over the past month. Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Previous Close:

$33.62

Open:

$33.82

24h Volume:

1.49M

Relative Volume:

0.28

Market Cap:

$24.59B

Revenue:

$8.26M

Net Income/Loss:

$-397.91M

P/E Ratio:

-67.60

EPS:

-0.5036

Net Cash Flow:

$-758.56M

1W Performance:

-0.48%

1M Performance:

-13.81%

6M Performance:

+15.84%

1Y Performance:

+100.38%

1-Day Range:

$33.70

$34.33

1-Week Range:

$33.00

$35.59

52-Week Range:

$16.00

$42.50

Roivant Sciences Ltd Stock (ROIV) Company Profile

Name

Roivant Sciences Ltd

Sector

Healthcare (1051)

Industry

Biotechnology (593)

Phone

441-295-5950

Address

7TH FLOOR, 50 BROADWAY, LONDON

Employee

721

Twitter

Next Earnings Date

2026-11-09

Latest SEC Filings

ROIV's Discussions on Twitter

Compare ROIV vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ROIV Roivant Sciences Ltd	34.05	24.59B	8.26M	-397.91M	-758.56M	-0.5036
VRTX Vertex Pharmaceuticals Inc	510.13	129.30B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	237.70	94.90B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	801.21	82.49B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	848.03	53.33B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	370.95	41.96B	5.76B	514.49M	1.10B	4.4813

Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-12-26	Downgrade	Wolfe Research	Outperform → Peer Perform
Sep-17-26	Initiated	Stifel	Buy
Mar-20-26	Initiated	Bernstein	Outperform
Sep-02-25	Initiated	Citigroup	Buy
Jul-10-25	Resumed	Goldman	Buy
Feb-15-24	Initiated	Wolfe Research	Outperform
Jan-05-24	Initiated	Piper Sandler	Overweight
Dec-12-23	Initiated	Deutsche Bank	Buy
Oct-17-23	Initiated	Guggenheim	Buy
Jun-08-23	Initiated	BofA Securities	Neutral
Oct-27-22	Initiated	JP Morgan	Overweight
May-23-22	Initiated	SVB Leerink	Outperform
Apr-29-22	Initiated	Cantor Fitzgerald	Overweight
Dec-15-21	Initiated	Goldman	Buy
Nov-08-21	Initiated	H.C. Wainwright	Buy
Oct-28-21	Initiated	Citigroup	Buy
Oct-26-21	Initiated	Cowen	Outperform
Oct-26-21	Initiated	Jefferies	Buy
Oct-26-21	Initiated	Truist	Buy

View All

Roivant Sciences Ltd Stock (ROIV) Latest News

Oct 05, 2026

At $5 a share, Arbutus Biopharma (ABUS) accepts tendered shares; Roivant retains about 19.5%. - Stock Titan

Oct 05, 2026

Roivant Sciences (ROIV) director exercises $4.46 options and sells 17,750 shares. - Stock Titan

Oct 05, 2026

Oct 02, 2026

Through a stock grant settlement, Frank Torti acquires 40,309 Roivant Sciences (ROIV) shares. - Stock Titan

Oct 02, 2026

CEO Matthew Gline holds 16.6 million shares after Roivant Sciences (ROIV) withholds 76,171 for taxes. - Stock Titan

Oct 02, 2026

Vesting triggers withholding of 46,879 shares from Roivant Sciences (ROIV) President Mayukh Sukhatme. - Stock Titan

Oct 02, 2026

After exercising $3.85 options, Eric Venker sells shares in Roivant Sciences (ROIV). - Stock Titan

Oct 02, 2026

Oct 01, 2026

Form 144 Roivant Sciences Ltd. For: 1 October By Investing.com - Investing.com Nigeria

Oct 01, 2026

Form 144 Roivant Sciences Ltd. For: 1 October By Investing.com - Investing.com Canada

Oct 01, 2026

Sep 30, 2026

After a $7.15M August sale, Roivant (ROIV) officer Eric Venker proposes another share sale. - Stock Titan

Sep 30, 2026

Sep 22, 2026

Roivant (ROIV) CAO uses 3,880 shares to cover RSU taxes - Stock Titan

Sep 22, 2026

Roivant Sciences (ROIV) CFO now holds 269,681 shares after RSU tax withholding - Stock Titan

Sep 22, 2026

Sep 18, 2026

Roivant Sciences (ROIV) director receives new 2027-vesting equity grant - Stock Titan

Sep 18, 2026

Roivant Sciences (ROIV) director now holds 8.97M shares - Stock Titan

Sep 18, 2026

New stock awards for Roivant Sciences (ROIV) director vest in 2027 - Stock Titan

Sep 18, 2026

Roivant Sciences (ROIV) grants director stock awards vesting in 2027 - Stock Titan

Sep 18, 2026

Roivant Sciences (ROIV) gives director new options and RSUs - Stock Titan

Sep 18, 2026

Director at Roivant (ROIV) receives new stock awards - Stock Titan

Sep 18, 2026

Sep 17, 2026

Roivant Sciences (NASDAQ: ROIV) director sells 4,938 shares under 10b5-1 plan - Stock Titan

Sep 17, 2026

Roivant Sciences (ROIV) director sells 5,112 shares under pre-set plan - Stock Titan

Sep 17, 2026

Sep 15, 2026

Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants (NASDAQ:ROIV) - Seeking Alpha

Sep 13, 2026